Surmodics Reports Fourth Quarter Fiscal 2019 Results and Issues Fiscal 2020 Revenue and EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Trump says Canada's Bombardier must build jets in US or lose market access
- Qualcomm to issue warrant to Amazon for up to 25M shares
- Wall St slips as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
SurModics (SRDX) PT Lowered to $63 at Needham & Company
November 1, 2019 7:30 AM EDTNeedham & Company analyst Mike Matson lowered the price target on SurModics (NASDAQ: SRDX) to $63.00 (from $68.00) while maintaining a Buy rating.
The analyst commented, "Full data from GALACTIC-HF remains on track for 2021. We continue to view omecamtiv as the backbone to our CYTK... More
SurModics (SRDX) Reports In-Line Q4 EPS, Revenues Beat; Offers FY20 EPS/Revenue Guidance Below Consensus
October 31, 2019 4:17 PM EDTSurModics (NASDAQ: SRDX) reported Q4 EPS of $0.37, in-line with the analyst estimate of $0.37. Revenue for the quarter came in at $30.8 million versus the consensus estimate of $28.36 million.
Summary of Fourth Quarter and Recent Highlights
Revenue of $30.8 million, an increase of 33.8% year-over-yearGAAP EPS of $0.26, non-GAAP EPS of $0.37Completed enrollment in TRANSCEND pivotal clinical trial for... More